Viemed Healthcare Q2 revenue rises on ventilator patient growth
VMD•Outlook
- Viemed raises 2026 net revenue guidance to $314 mln-$320 mln from $312 mln-$320 mln
- Company revises 2026 Adjusted EBITDA outlook to $64 mln-$68 mln from $65 mln-$69 mln
- Net capital expenditures for 2026 now seen at 8.5%-10.0% of net revenue, down from 9.0%-10.5%
Result drivers
- Ventilator patient growth - Co said record ventilator patient census and strong setup activity contributed to revenue growth
- PAP and resupply expansion - Co cited record PAP therapy volume and continued expansion in resupply and maternal health as supporting growth
- Diversified platform - CEO said results reflect a more diversified business with multiple growth engines and ongoing investments in technology and patient care
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the healthcare facilities & services peer group is "buy"
- Wall Street's median 12-month price target for Viemed Healthcare Inc is $13.00, about 11.4% above its July 31 closing price of $11.67
- The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 19 three months ago
